Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

thinkemotive

- PMLiVE

Sanofi, Regeneron’s Libtayo scores first-line NSCLC approval in the US

New approval will see Libtayo compete with blockbuster immunotherapy Keytruda

- PMLiVE

FDA fast-tracks review of Incyte’s Jakafi for chronic GVHD

Submission is based on results from the pivotal REACH3 study

- PMLiVE

Dan Carucci becomes global chief medical officer of McCann Health

Carucci initially joined McCann in February 2018 as medical director

Looking back at the year when everything changed

COVID-19 has impacted every aspect of our lives, from the way we shop for groceries to the way we conduct work and interact with healthcare providers and our families.

Impetus Digital

- PMLiVE

WHO agrees to no-fault compensation for rare serious side effects from COVAX-distributed vaccines

The no-fault compensation fund will be accessible via a web portal by 31 March 2021

- PMLiVE

EU set to contribute €1bn to COVAX

EU had already pledged €500m to the international vaccine-sharing facility

- PMLiVE

Rare Disease Day – why it’s important to show your stripes

Nucleus Global's EU Strategy Director, Amanda Henkel, writes about the importance of continuing to raise awareness of rare diseases

Nucleus Global

- PMLiVE

Genmab appoints Tahamtan Ahmadi as chief medical officer, head of experimental medicines

Ahmadi joined Genmab in 2017, previously serving as senior vice president, head of oncology

- PMLiVE

Back to the future

Five years ago, an influential book used Darwin’s ideas to predict the future of the industry – how did that work out?

- PMLiVE

UK approval for Seagen’s oral HER2 inhibitor Tukysa

MHRA has authorised drug for HER2-positive advanced breast cancer

- PMLiVE

AZ withdraws Imfinzi in the US for advanced bladder cancer after post-marketing study fail

Immunotherapy failed to hit primary endpoint in phase 3 DANUBE trial last year

- PMLiVE

First dose of Pfizer/BioNTech vaccine reduces COVID-19 infection risk by 70%

COVID-19 vaccines are also reducing risk of hospitalisation

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links